Abstract | BACKGROUND: METHODS: Synovial fluid was obtained from patients with active rheumatoid arthritis (RA), PsA or peripheral spondyloarthritis (SpA; n = 18). The in vitro models consisted of synovial fluid mononuclear cells (SFMCs) or fibroblast-like synovial cells (FLSs) cultured for 48 h, SFMCs cultured for 21 days, an osteoclast pit formation assay, and a mineralization assay. RESULTS: CONCLUSION: This study reveals the downstream effects of apremilast in ex vivo models of arthritis with a strong inhibition of IL-12/IL-23p40 by SFMCs. Our findings could explain some of the efficacy of apremilast seen in IL-12/IL-23-driven immune-mediated inflammatory diseases such as psoriasis and PsA.
|
Authors | Tue W Kragstrup, Mary Adams, Søren Lomholt, Morten A Nielsen, Line D Heftdal, Peter Schafer, Bent Deleuran |
Journal | Therapeutic advances in musculoskeletal disease
(Ther Adv Musculoskelet Dis)
Vol. 11
Pg. 1759720X19828669
( 2019)
ISSN: 1759-720X [Print] England |
PMID | 30833991
(Publication Type: Journal Article)
|